Forest, Merz to sue generic companies over Namenda patents

NEW YORK Forest Laboratories and Merz have announced that they are suing several generic drug manufacturers, alleging patent infringements on the Alzheimer’s disease drug Namenda, according to the Associated Press.

The suits, which were filed in the U.S. District Court for the District of Delaware were filed against, Barr Laboratories, Cobalt Laboratories, Lupin, Orchid Chemicals & Pharmaceuticals, Teva Pharmaceuticals USA , Upsher-Smith Laboratories and Wockhardt.

Forest claims its patent for Namenda does not expire until April 2010, and that it is seeking patent extension approval through September 2013. Namenda generated sales of $192.9 million during the second quarter of fiscal 2008.